Asset Management One Co. Ltd. Acquires 21,545 Shares of Kenvue Inc. (NYSE:KVUE)

Asset Management One Co. Ltd. increased its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 3.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 749,580 shares of the company's stock after acquiring an additional 21,545 shares during the period. Asset Management One Co. Ltd.'s holdings in Kenvue were worth $16,138,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in KVUE. State Street Corp grew its stake in shares of Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after acquiring an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock worth $2,011,832,000 after purchasing an additional 7,115,374 shares during the last quarter. Holocene Advisors LP raised its position in shares of Kenvue by 75.5% during the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company's stock valued at $321,194,000 after buying an additional 5,975,392 shares during the last quarter. M&G PLC raised its position in shares of Kenvue by 538.0% during the third quarter. M&G PLC now owns 4,341,172 shares of the company's stock valued at $99,847,000 after buying an additional 3,660,730 shares during the last quarter. Finally, FMR LLC raised its position in shares of Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company's stock valued at $3,189,985,000 after buying an additional 3,075,019 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Trading Up 1.2 %

NYSE:KVUE traded up $0.26 during mid-day trading on Wednesday, hitting $22.26. The company had a trading volume of 14,194,931 shares, compared to its average volume of 13,257,708. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The firm has a market cap of $42.68 billion, a P/E ratio of 42.00, a P/E/G ratio of 2.57 and a beta of 1.45. The business's fifty day moving average is $21.30 and its two-hundred day moving average is $22.12.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.68%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's dividend payout ratio is currently 154.72%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on KVUE shares. Barclays cut their price objective on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Bank of America upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Piper Sandler raised shares of Kenvue from a "neutral" rating to an "overweight" rating and upped their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.